한글목차

파지 치료 시장 규모는 2024년에 5,525만 달러로 평가되었고, 2025-2031년의 예측 기간 중 CAGR 19.3%로 성장하여 2031년까지 1억 8,900만 달러로 확대될 것으로 예측됩니다.

파지(정식명칭: 박테리오파지)는 박테리아만 선택적으로 사멸시키는 바이러스입니다. 자연계에서 가장 보편적인 생물학적 실체이며, 다제내성균을 효과적으로 퇴치하고 파괴하는 것으로 입증되었습니다. 즉, 모든 항생제가 효력을 잃었을 때에도 파지는 세균을 죽이는 데 성공하여 감염으로부터 생명을 구할 수 있습니다. 파지는 인간 의학뿐만 아니라 치과, 수의학, 농업 등에도 많은 잠재적 응용 가능성을 가지고 있습니다.

박테리오파지 시장은 항생제 내성 감염증 증가, 새로운 치료법에 대한 연구개발 활성화, 시장 기업들의 인수 및 제휴와 같은 성장 전략의 채택 확대로 인해 높은 성장률을 보일 것으로 예측됩니다.

박테리오파지는 박테리아에 부착하여 숙주 세포를 감염시켜 최종적으로 파괴하는 바이러스의 일종입니다. 이 미생물은 인간이나 동물의 세포와 상호작용하지 않고 자연적 과정을 통해 숙주 세포를 파괴합니다. 박테리오파지의 활용이 특히 중요하게 여겨지는 분야 중 하나는 가금류 및 양식업입니다. 현대 의학에서 인간에 대한 박테리오파지의 사용은 아직 드물지만, 축산, 가금류 및 어류 사육 분야에서는 이미 좋은 결과를 보이고 있습니다.

박테리오파지 분야의 주요 세계 기업으로는 NPO Microgen, Qingdao Phagepharm Bio-tech, Armata Pharmaceuticals, Inc. BioPreparations, Intralytix, MicroMir, Phagelux, Pharmex Group, LLC 등이 있습니다. 2024년 기준, 세계 상위 5개 벤더의 매출 점유율은 약 48%를 차지했습니다.

이 보고서는 세계 파지 치료 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

파지 치료 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 포지셔닝을 분석하고, 파지 치료와 관련된 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

• NPO Microgen
• Qingdao Phagepharm Bio-tech
• Armata Pharmaceuticals, Inc.
• Phaxiam Therapeutics
• Eliava BioPreparations
• Intralytix
• MicroMir
• Phagelux
• Pharmex Group, LLC
• APS Biocontrol Ltd.(APS)
• ACD Pharma
• Proteon Pharmaceuticals
• Micreos
• Locus Biosciences, Inc
• NexaBiome Limited
• PhagePro
• BiomX
• INtODEWORLD, Inc.
• TechnoPhage
• PhageLab
• SciPhage
• Kinzbio

유형별 부문

• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• 기타

용도별 부문

• 인간 건강
• 동물 건강
• 수산양식
• 농업
• 식품 산업
• 기타

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동 및 아프리카

영문목차

The global market for Phage Therapy was estimated to be worth US$ 55.25 million in 2024 and is forecast to a readjusted size of US$ 189 million by 2031 with a CAGR of 19.3% during the forecast period 2025-2031.

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

The Bacteriophage market is expected to grow at a significant rate owing to rising prevalence of antibiotic resistant infection, rising research activities for and development of novel therapies, increasing adoption of growth strategies such as acquisitions, and collaborations by market players.

Bacteriophage is a type of virus that attaches itself to a bacterium and infects the host cell, subsequently destroying it. These microorganisms destroy their host cells through a natural process without interacting with human or animal cells. One of the most important sectors where the use of bacteriophages has emerged as very important is the poultry and aquaculture. While the use of bacteriophages in humans is still a rarity in modern medicine, their usage in animal husbandry, rearing poultry and fish is already showing positive results.

The major global companies of Bacteriophage include NPO Microgen, Qingdao Phagepharm Bio-tech, Armata Pharmaceuticals, Inc., Phaxiam Therapeutics, Eliava BioPreparations, Intralytix, MicroMir, Phagelux, and Pharmex Group, LLC, etc. In 2024, the world's top five vendors accounted for approximately 48% of the revenue.

This report aims to provide a comprehensive presentation of the global market for Phage Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phage Therapy by region & country, by Type, and by Application.

The Phage Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phage Therapy.

Market Segmentation

By Company

• NPO Microgen
• Qingdao Phagepharm Bio-tech
• Armata Pharmaceuticals, Inc.
• Phaxiam Therapeutics
• Eliava BioPreparations
• Intralytix
• MicroMir
• Phagelux
• Pharmex Group, LLC
• APS Biocontrol Ltd. (APS)
• ACD Pharma
• Proteon Pharmaceuticals
• Micreos
• Locus Biosciences, Inc
• NexaBiome Limited
• PhagePro
• BiomX
• INtODEWORLD, Inc.
• TechnoPhage
• PhageLab
• SciPhage
• Kinzbio

Segment by Type

• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Segment by Application

• Human Health
• Animal Health
• Aquaculture
• Agriculture
• Food Industry
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Phage Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Phage Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Phage Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Phage Therapy Product Introduction
• 1.2 Global Phage Therapy Market Size Forecast (2020-2031)
• 1.3 Phage Therapy Market Trends & Drivers
  • 1.3.1 Phage Therapy Industry Trends
  • 1.3.2 Phage Therapy Market Drivers & Opportunity
  • 1.3.3 Phage Therapy Market Challenges
  • 1.3.4 Phage Therapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Phage Therapy Players Revenue Ranking (2024)
• 2.2 Global Phage Therapy Revenue by Company (2020-2025)
• 2.3 Key Companies Phage Therapy Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Phage Therapy Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Phage Therapy
• 2.6 Phage Therapy Market Competitive Analysis
  • 2.6.1 Phage Therapy Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Phage Therapy Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phage Therapy as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 DsDNA Bacteriophage
  • 3.1.2 SsDNA Bacteriophage
  • 3.1.3 SsRNA Bacteriophage
  • 3.1.4 Others
• 3.2 Global Phage Therapy Sales Value by Type
  • 3.2.1 Global Phage Therapy Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Phage Therapy Sales Value, by Type (2020-2031)
  • 3.2.3 Global Phage Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Human Health
  • 4.1.2 Animal Health
  • 4.1.3 Aquaculture
  • 4.1.4 Agriculture
  • 4.1.5 Food Industry
  • 4.1.6 Others
• 4.2 Global Phage Therapy Sales Value by Application
  • 4.2.1 Global Phage Therapy Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Phage Therapy Sales Value, by Application (2020-2031)
  • 4.2.3 Global Phage Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Phage Therapy Sales Value by Region
  • 5.1.1 Global Phage Therapy Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Phage Therapy Sales Value by Region (2020-2025)
  • 5.1.3 Global Phage Therapy Sales Value by Region (2026-2031)
  • 5.1.4 Global Phage Therapy Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Phage Therapy Sales Value, 2020-2031
  • 5.2.2 North America Phage Therapy Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Phage Therapy Sales Value, 2020-2031
  • 5.3.2 Europe Phage Therapy Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Phage Therapy Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Phage Therapy Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Phage Therapy Sales Value, 2020-2031
  • 5.5.2 South America Phage Therapy Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Phage Therapy Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Phage Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Phage Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Phage Therapy Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Phage Therapy Sales Value, 2020-2031
  • 6.3.2 United States Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Phage Therapy Sales Value, 2020-2031
  • 6.4.2 Europe Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Phage Therapy Sales Value, 2020-2031
  • 6.5.2 China Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Phage Therapy Sales Value, 2020-2031
  • 6.6.2 Japan Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Phage Therapy Sales Value, 2020-2031
  • 6.7.2 South Korea Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Phage Therapy Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Phage Therapy Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Phage Therapy Sales Value, 2020-2031
  • 6.9.2 India Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Phage Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 NPO Microgen
  • 7.1.1 NPO Microgen Profile
  • 7.1.2 NPO Microgen Main Business
  • 7.1.3 NPO Microgen Phage Therapy Products, Services and Solutions
  • 7.1.4 NPO Microgen Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.1.5 NPO Microgen Recent Developments
• 7.2 Qingdao Phagepharm Bio-tech
  • 7.2.1 Qingdao Phagepharm Bio-tech Profile
  • 7.2.2 Qingdao Phagepharm Bio-tech Main Business
  • 7.2.3 Qingdao Phagepharm Bio-tech Phage Therapy Products, Services and Solutions
  • 7.2.4 Qingdao Phagepharm Bio-tech Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Qingdao Phagepharm Bio-tech Recent Developments
• 7.3 Armata Pharmaceuticals, Inc.
  • 7.3.1 Armata Pharmaceuticals, Inc. Profile
  • 7.3.2 Armata Pharmaceuticals, Inc. Main Business
  • 7.3.3 Armata Pharmaceuticals, Inc. Phage Therapy Products, Services and Solutions
  • 7.3.4 Armata Pharmaceuticals, Inc. Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Armata Pharmaceuticals, Inc. Recent Developments
• 7.4 Phaxiam Therapeutics
  • 7.4.1 Phaxiam Therapeutics Profile
  • 7.4.2 Phaxiam Therapeutics Main Business
  • 7.4.3 Phaxiam Therapeutics Phage Therapy Products, Services and Solutions
  • 7.4.4 Phaxiam Therapeutics Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Phaxiam Therapeutics Recent Developments
• 7.5 Eliava BioPreparations
  • 7.5.1 Eliava BioPreparations Profile
  • 7.5.2 Eliava BioPreparations Main Business
  • 7.5.3 Eliava BioPreparations Phage Therapy Products, Services and Solutions
  • 7.5.4 Eliava BioPreparations Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Eliava BioPreparations Recent Developments
• 7.6 Intralytix
  • 7.6.1 Intralytix Profile
  • 7.6.2 Intralytix Main Business
  • 7.6.3 Intralytix Phage Therapy Products, Services and Solutions
  • 7.6.4 Intralytix Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Intralytix Recent Developments
• 7.7 MicroMir
  • 7.7.1 MicroMir Profile
  • 7.7.2 MicroMir Main Business
  • 7.7.3 MicroMir Phage Therapy Products, Services and Solutions
  • 7.7.4 MicroMir Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.7.5 MicroMir Recent Developments
• 7.8 Phagelux
  • 7.8.1 Phagelux Profile
  • 7.8.2 Phagelux Main Business
  • 7.8.3 Phagelux Phage Therapy Products, Services and Solutions
  • 7.8.4 Phagelux Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Phagelux Recent Developments
• 7.9 Pharmex Group, LLC
  • 7.9.1 Pharmex Group, LLC Profile
  • 7.9.2 Pharmex Group, LLC Main Business
  • 7.9.3 Pharmex Group, LLC Phage Therapy Products, Services and Solutions
  • 7.9.4 Pharmex Group, LLC Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Pharmex Group, LLC Recent Developments
• 7.10 APS Biocontrol Ltd. (APS)
  • 7.10.1 APS Biocontrol Ltd. (APS) Profile
  • 7.10.2 APS Biocontrol Ltd. (APS) Main Business
  • 7.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Products, Services and Solutions
  • 7.10.4 APS Biocontrol Ltd. (APS) Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.10.5 APS Biocontrol Ltd. (APS) Recent Developments
• 7.11 ACD Pharma
  • 7.11.1 ACD Pharma Profile
  • 7.11.2 ACD Pharma Main Business
  • 7.11.3 ACD Pharma Phage Therapy Products, Services and Solutions
  • 7.11.4 ACD Pharma Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.11.5 ACD Pharma Recent Developments
• 7.12 Proteon Pharmaceuticals
  • 7.12.1 Proteon Pharmaceuticals Profile
  • 7.12.2 Proteon Pharmaceuticals Main Business
  • 7.12.3 Proteon Pharmaceuticals Phage Therapy Products, Services and Solutions
  • 7.12.4 Proteon Pharmaceuticals Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Proteon Pharmaceuticals Recent Developments
• 7.13 Micreos
  • 7.13.1 Micreos Profile
  • 7.13.2 Micreos Main Business
  • 7.13.3 Micreos Phage Therapy Products, Services and Solutions
  • 7.13.4 Micreos Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Micreos Recent Developments
• 7.14 Locus Biosciences, Inc
  • 7.14.1 Locus Biosciences, Inc Profile
  • 7.14.2 Locus Biosciences, Inc Main Business
  • 7.14.3 Locus Biosciences, Inc Phage Therapy Products, Services and Solutions
  • 7.14.4 Locus Biosciences, Inc Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Locus Biosciences, Inc Recent Developments
• 7.15 NexaBiome Limited
  • 7.15.1 NexaBiome Limited Profile
  • 7.15.2 NexaBiome Limited Main Business
  • 7.15.3 NexaBiome Limited Phage Therapy Products, Services and Solutions
  • 7.15.4 NexaBiome Limited Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.15.5 NexaBiome Limited Recent Developments
• 7.16 PhagePro
  • 7.16.1 PhagePro Profile
  • 7.16.2 PhagePro Main Business
  • 7.16.3 PhagePro Phage Therapy Products, Services and Solutions
  • 7.16.4 PhagePro Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.16.5 PhagePro Recent Developments
• 7.17 BiomX
  • 7.17.1 BiomX Profile
  • 7.17.2 BiomX Main Business
  • 7.17.3 BiomX Phage Therapy Products, Services and Solutions
  • 7.17.4 BiomX Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.17.5 BiomX Recent Developments
• 7.18 INtODEWORLD, Inc.
  • 7.18.1 INtODEWORLD, Inc. Profile
  • 7.18.2 INtODEWORLD, Inc. Main Business
  • 7.18.3 INtODEWORLD, Inc. Phage Therapy Products, Services and Solutions
  • 7.18.4 INtODEWORLD, Inc. Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.18.5 INtODEWORLD, Inc. Recent Developments
• 7.19 TechnoPhage
  • 7.19.1 TechnoPhage Profile
  • 7.19.2 TechnoPhage Main Business
  • 7.19.3 TechnoPhage Phage Therapy Products, Services and Solutions
  • 7.19.4 TechnoPhage Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.19.5 TechnoPhage Recent Developments
• 7.20 PhageLab
  • 7.20.1 PhageLab Profile
  • 7.20.2 PhageLab Main Business
  • 7.20.3 PhageLab Phage Therapy Products, Services and Solutions
  • 7.20.4 PhageLab Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.20.5 PhageLab Recent Developments
• 7.21 SciPhage
  • 7.21.1 SciPhage Profile
  • 7.21.2 SciPhage Main Business
  • 7.21.3 SciPhage Phage Therapy Products, Services and Solutions
  • 7.21.4 SciPhage Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.21.5 SciPhage Recent Developments
• 7.22 Kinzbio
  • 7.22.1 Kinzbio Profile
  • 7.22.2 Kinzbio Main Business
  • 7.22.3 Kinzbio Phage Therapy Products, Services and Solutions
  • 7.22.4 Kinzbio Phage Therapy Revenue (US$ Million) & (2020-2025)
  • 7.22.5 Kinzbio Recent Developments

8 Industry Chain Analysis

• 8.1 Phage Therapy Industrial Chain
• 8.2 Phage Therapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Phage Therapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Phage Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer